Table 2. Peak concentration of HIV-1 gp41-specific antibodies in plasma and mucosal samples observed during Fiebig stage III through V/VI of AHI.
|
Plasma gp41-specific Ab (μg/ml) |
Mucosal gp41-specific Ab (μg/mg) |
|||||
|---|---|---|---|---|---|---|
| Number positive (n) | Median (range) | Mean±s.d. | Number positive (n) | Median (range) | Mean±s.d. | |
| IgG | ||||||
| All | 23 | 546.3 (5.4–5194.8) | 1242.4±1485.8 | 12 | 35.6 (2.4–444.9) | 102.7±133.7 |
| Male | 16 | 1300.1 (5.4–5194.8) | 1618.8±1632.8 | 9 | 32.5 (2.4–444.9) | 111.2±151.8 |
| Female | 7 | 353.5 (128.8–1761.1) | 555.4±554.8 | 3 | 72.1 (10.6–148.1 ) | 76.0±68.9 |
| IgA | ||||||
| All | 23 | 12.5 (0.7–41.2) | 12.5±9.4 | 12 | 4.4 (0.4–52.4) | 9.2±14.2 |
| Male | 16 | 13.0 (0.7–41.2) | 14.4± 10.3 | 9 | 9.0 (0.7–52.4) | 11.6±15.7 |
| Female | 7 | 4.8 (1.2–13.0) | 7.0±4.6 | 3 | 0.8 (0.4–3.2) | 1.4±1.5 |
| IgM | ||||||
| All | 12 | 7.9 (0.3–26.7) | 9.8±8.0 | 5 | 26,939 (15,110–112,989) | 40,719±40,780 |
| Male | 10 | 6.7 (0.3–13.7) | 6.9±4.2 | 5 | 26,939 (15,110–112,989) | 40,719±40,780 |
| Female | 2 | 24.8 (22.9–26.7) | 24.8±2.7 | 0 | — | — |
Abbreviations: Ab, antibody; AHI, acute HIV-1 infection; Ig, immunoglobulin.
Peak plasma and mucosal HIV-1 gp41-specific antibody levels were determined in CHAVI 001 patients during the first 133 days post enrollment. Concentration is expressed in μg/ml equivalents determined with a standard curve using 2F5 IgG, IgA, or IgM. Mucosal antibody levels are expressed as specific activity (μg of gp41-specific antibody/mg of total antibody).